PETER CHANG: Open Payments
NPI 1780688028 · SAN ANGELO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,662 in 52 payments from 15 companies in 2025. Trend: 2023 $727 · 2024 $9,488 · 2025 $5,662
Consulting: $4,675Food & beverage: $967Education: $20
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $4,861 |
| Ardelyx, Inc. | 11 | $388 |
| Novo Nordisk Inc | 4 | $62 |
| Neurocrine BioSciences, Inc. | 3 | $52 |
| Axsome Therapeutics, Inc. | 3 | $51 |
| Lilly USA, LLC | 2 | $44 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| AstraZeneca Pharmaceuticals LP | 2 | $38 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $25 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $20 |
Products named: XEN GLAUCOMA TREATMENT SYSTEM, DURYSTA, IBSRELA, VRAYLAR, UBRELVY, REXULTI, INGREZZA, Auvelity.
Industry payments across TX — which companies pay providers there.
